Delivery Order SPE2DB24D2100-SPE2DB25FBFVH
- Not listed
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for Dexmethylphenidate ER 10 mg capsules in a quantity of 100 units at a ceiling value of $3,265.34. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, reflecting the vendor's established capability to meet federal pharmaceutical procurement requirements through open competition. The contract will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Dexmethylphenidate ER 15 mg in quantities of 100 capsules at a ceiling value of $1,253.86. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open competition process. The order is scheduled for completion by September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100-count) with a ceiling value of $1,202.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for ultimate completion by August 7, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $1,929.35 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Dexmethylphenidate ER 20 mg in quantities of 100 capsules. This is a firm fixed price, competitively awarded contract with an ultimate completion date of September 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside award, indicating open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with a ceiling value of $1,226.04. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100-count) with a ceiling value of $3,690.82. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for ultimate completion by June 2, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,148.12 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 30 mg capsules (100 count) with an ultimate completion date of July 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 30 mg capsules (100 count) valued at $1,722.69, with an ultimate completion date of September 10, 2025. This is a firm fixed-price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. Dexmethylphenidate is...
- The Defense Logistics Agency awarded a $10,485.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with an ultimate completion date of September 19, 2025. This non-set-aside contract was competitively awarded and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare vendor,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 30 mg capsules (100 count) on August 5, 2025, with a ceiling value of $2,111.70 and an ultimate completion date of August 6, 2025. This is a firm fixed price delivery order with no set-aside designation, executed under competitive procedures. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB25FBFVHDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,815.80 for Dexmethylphenidate ER 10 mg capsules (100 count) on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dexmethylphenidate is a central nervous system stimulant commonly prescribed for attention deficit hyperactivity disorder (ADHD) treatment in military and veteran healthcare populations. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs globally. The underlying IDC represents DLA's pharmaceutical support vehicle for the Defense Health Agency and other federal healthcare systems, allowing for flexible fulfillment of ongoing medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 8/13/25 |